The Cancer You Can't See: What Is MRD?
When cancer treatment ends and scans look clear, an important question may remain: Could cancer cells still be hiding in the body? Discover how a powerful approach called MRD testing is helping researchers and doctors look closer.
Imagine finishing cancer treatment and hearing the words you've been waiting for:
"We can't find any evidence of cancer."
It's a moment that can bring enormous relief.
But for many people, another question quietly follows.
How do we know it's really gone?
Traditional scans, blood tests, and other examinations are essential tools for monitoring cancer. But even our most advanced technology has limits. Sometimes tiny amounts of cancer can remain in the body without being detected through standard testing.
Now scientists have developed highly sensitive tests that can sometimes detect evidence of cancer at an incredibly small scale.
It's called MRD, or measurable residual disease, also known as minimal residual disease.
And it's one of the most intriguing developments in cancer research.
What Exactly Is MRD?
Think of cancer treatment like putting out a fire.
The flames are gone. The smoke has cleared. Everything appears normal.
But could a few hidden embers remain?
That's essentially the question MRD testing tries to answer.
MRD refers to small amounts of cancer that may remain during or after treatment but are too difficult to detect using conventional tests.
In certain blood cancers, such as leukemia and multiple myeloma, highly sensitive tests can identify tiny numbers of remaining cancer cells.
For solid tumors, including cancers of the colon, breast, and lung, researchers are increasingly studying ways to detect microscopic evidence of remaining cancer by looking for fragments of tumor DNA.
The goal is to gather information that traditional imaging or laboratory tests might miss.
How Can a Blood Test Find Cancer That a Scan Can't?
Here's where the science gets fascinating.
As cells die or break down, they can release small fragments of DNA into the bloodstream.
Cancer cells can do this, too.
These fragments are called circulating tumor DNA, or ctDNA.
Using specialized laboratory technology, researchers can sometimes detect tumor-related DNA in a blood sample, even when there isn't enough cancer present to show up on a scan.
This is one form of liquid biopsy.
Some tests use genetic information from a person's original tumor to look for matching DNA in their blood. Others look for selected tumor-related genetic changes without requiring a previously analyzed tumor sample.
Importantly, not all MRD testing involves circulating tumor DNA. For blood cancers, doctors may examine bone marrow or blood cells using other highly sensitive techniques.
The right approach depends on the cancer and the clinical situation.
What Does an MRD Result Actually Mean?
MRD testing generally produces one of two findings.
MRD-positive: The test detected evidence of residual cancer within its detection capabilities.
MRD-negative: The test did not detect residual cancer at the time of testing.
But here's the important distinction.
MRD-negative does not necessarily mean every cancer cell is gone.
The amount of cancer may be below the test's detection limit, or the cancer may not be releasing enough detectable DNA into the blood.
And MRD-positive does not automatically mean that a visible cancer recurrence has occurred or that it definitely will.
Doctors must interpret results in the context of the cancer type, treatment history, test used, and other clinical findings.
Why Is MRD Such a Big Deal?
Because it could help answer questions that have challenged cancer medicine for decades.
Did treatment eliminate the cancer?
Who might be at greater risk of recurrence?
Who could benefit from additional treatment?
And who might be able to avoid unnecessary treatment and its side effects?
For some blood cancers, MRD testing is already an established part of assessing treatment response and can help guide care.
For many solid tumors, research has shown that detectable circulating tumor DNA after treatment is associated with a greater likelihood of recurrence.
But there's a crucial difference between identifying a higher risk and knowing exactly what to do about it.
Detecting a molecular warning sign doesn't automatically mean that changing treatment will improve someone's outcome.
That's one of the biggest questions researchers are working to answer.
Could MRD Change Cancer Treatment?
Potentially, yes.
Imagine a future in which doctors can use highly sensitive tests to better identify who needs additional therapy after surgery and who may safely avoid it.
Instead of giving the same post-surgery treatment to everyone with a similar diagnosis, care could become more tailored to the individual's actual risk.
Clinical trials are investigating this possibility in colorectal, breast, lung, and other cancers.
The science is promising, but it is evolving.
According to 2026 guidance from the American Society of Clinical Oncology, evidence is still insufficient to recommend routine ctDNA-based MRD monitoring broadly across solid tumors. Research has not yet established that acting on these results improves outcomes in most settings.
MRD testing should not replace established scans, examinations, or recommended follow-up care simply because a blood test is available.
Should Everyone Who Has Had Cancer Get an MRD Test?
Not necessarily.
MRD testing is more established for certain blood cancers than for most solid tumors.
Whether it makes sense depends on the type and stage of cancer, the treatment received, the available tests, and whether the results would meaningfully affect medical decisions.
Cost and insurance coverage may also be considerations.
If you're interested in MRD testing, ask your oncologist whether it is recommended for your situation or being offered through an appropriate clinical trial.
And remember: More testing isn't always better if the results cannot reliably guide the next step.
Questions Worth Asking Your Healthcare Team
If you're receiving cancer treatment or navigating life after treatment, consider these questions:
Is MRD testing available and appropriate for my type of cancer?
What would a positive or negative result actually mean for me?
Would the result change my treatment or follow-up plan?
Are there clinical trials studying MRD testing for my cancer?
What are the limitations, costs, and potential benefits?
You deserve to understand what a test can tell you, and just as importantly, what it cannot.
The Bottom Line: Seeing Less Could Help Us Understand More
One of the greatest challenges in cancer care has always been understanding what happens after treatment.
MRD testing is giving researchers and healthcare professionals new ways to investigate that question.
For certain cancers, it already provides valuable information. For others, it represents an exciting area of research that could eventually make treatment decisions more precise.
But it isn't a guarantee of a cure, and it isn't a crystal ball.
The real promise of MRD isn't simply finding smaller traces of cancer.
It's learning how to use that information to help people receive the right care, at the right time, with greater confidence.
Take the Next Step
Ask What Your Test Results Really Mean
If you're navigating cancer treatment or follow-up care, talk with your healthcare team about MRD, biomarker testing, and whether emerging technologies might play a role in your care.
Explore Touch4Life's resources on biomarkers, precision medicine, and clinical trials to learn more about how cancer science is evolving.
Sources & Further Reading
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about MRD testing, cancer surveillance, and treatment decisions.
Comments